首页> 美国卫生研究院文献>Frontiers in Bioengineering and Biotechnology >Strategies to improve the therapeutic efficacy of mesenchymal stem cell‐derived extracellular vesicle (MSC-EV): a promising cell-free therapy for liver disease
【2h】

Strategies to improve the therapeutic efficacy of mesenchymal stem cell‐derived extracellular vesicle (MSC-EV): a promising cell-free therapy for liver disease

机译:提高间充质干细胞衍生的细胞外囊泡 (MSC-EV) 治疗效果的策略:一种很有前途的肝病无细胞疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Liver disease has emerged as a significant worldwide health challenge due to its diverse causative factors and therapeutic complexities. The majority of liver diseases ultimately progress to end-stage liver disease and liver transplantation remains the only effective therapy with the limitations of donor organ shortage, lifelong immunosuppressants and expensive treatment costs. Numerous pre-clinical studies have revealed that extracellular vesicles released by mesenchymal stem cells (MSC-EV) exhibited considerable potential in treating liver diseases. Although natural MSC-EV has many potential advantages, some characteristics of MSC-EV, such as heterogeneity, uneven therapeutic effect, and rapid clearance in vivo constrain its clinical translation. In recent years, researchers have explored plenty of ways to improve the therapeutic efficacy and rotation rate of MSC-EV in the treatment of liver disease. In this review, we summarized current strategies to enhance the therapeutic potency of MSC-EV, mainly including optimization culture conditions in MSC or modifications of MSC-EV, aiming to facilitate the development and clinical application of MSC-EV in treating liver disease.
机译:由于其多种致病因素和治疗复杂性,肝病已成为一项重大的全球性健康挑战。大多数肝脏疾病最终发展为终末期肝病,肝移植仍然是唯一有效的治疗方法,但存在供体器官短缺、终身免疫抑制剂和昂贵的治疗费用等局限性。大量临床前研究表明,间充质干细胞 (MSC-EV) 释放的细胞外囊泡在治疗肝脏疾病方面表现出相当大的潜力。尽管天然 MSC-EV 具有许多潜在优势,但 MSC-EV 的一些特性,如异质性、治疗效果不均匀和体内快速清除限制了其临床转化。近年来,研究人员探索了许多提高 MSC-EV 治疗肝病治疗疗效和旋转速率的方法。本文总结了目前提高 MSC-EV 治疗效能的策略,主要包括优化 MSC 培养条件或 MSC-EV 的修饰,旨在促进 MSC-EV 治疗肝病的开发和临床应用。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号